XML 93 R80.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION - Significant expense categories (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
SEGMENT INFORMATION    
Total research and development $ 6,916,181 $ 15,594,442
Selling, general and administrative    
Stock-based compensation 3,800,000 4,200,000
Selling, general and administrative 34,995,749 38,307,415
Capital expenditures of the segment 669,430 936,236
As previously reported    
Selling, general and administrative    
Legal, financial and other consulting 4,272,296  
Selling, general and administrative 33,600,065  
Single reportable segment    
SEGMENT INFORMATION    
Clinical expenses (4,482,691)  
Other research and development expenses (2,433,490)  
Total research and development 6,916,181  
Selling, general and administrative    
Commission expense 2,903,705  
Royalty expense 1,869,016  
Stock-based compensation 3,759,534  
Legal, financial and other consulting 3,178,787  
Other general and administrative 23,244,707  
Selling, general and administrative $ 34,995,749  
Single reportable segment | As previously reported    
SEGMENT INFORMATION    
Clinical expenses   (11,329,684)
Other research and development expenses   (4,264,758)
Total research and development   15,594,442
Selling, general and administrative    
Commission expense   2,289,773
Royalty expense   2,156,323
Stock-based compensation   4,155,341
Legal, financial and other consulting   4,272,296
Other general and administrative   25,433,682
Selling, general and administrative   $ 38,307,415